Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

PA-25-121: Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)

Closed Closed May 7, 2025 Opportunity PA-25-121

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.

National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 7, 2025.

From the official notice on Grants.gov, last changed October 10, 2024. Checked November 7, 2026.

About this NIH notice

Projects funded under PA-25-121 were run by National Cancer Institute (NCI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.

Application due dates, page limits and budget limits are set in the notice. Read PA-25-121 in the NIH Guide.

Other notices with this title

National Institutes of Health has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
PAR-22-083January 21, 2022Closed November 6, 2024Closed

Key dates

PostedOctober 10, 2024
DeadlineMay 7, 2025
Archived by Grants.govJune 12, 2025

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

All 15 applicant types the notice lists

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Category: Education, Health.

Funded under PA-25-121 so far

NIH funded 1 project under PA-25-121 in fiscal 2026, at 1 institution. The median yearly award was $681,676.

Recently funded projects
ProjectInstitutionFiscal yearAward
PFAS and liver cancer: linking epidemiological evidence with mechanistic studies R01University of Southern California2026$681,676

From NIH RePORTER, which lists each project once per fiscal year it was funded. Amounts are the yearly award.

Who has won Cancer Cause and Prevention Research grants before

From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Univeristy of Texas M.D. Anderson Cancer CenterTexas81$107 million
Sloan-Kettering Institute for Cancer ResearchNew York65$99.1 million
The Trustees of Columbia University in the City of New YorkNew York48$85.3 million
Dana-Farber Cancer Institute, Inc.Massachusetts51$83.1 million
University of North Carolina at Chapel HillNorth Carolina49$76.1 million

Top states: California ($465 million), New York ($445 million), Massachusetts ($350 million), Texas ($259 million), Pennsylvania ($175 million).

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is PA-25-121 still open?

No. It closed on May 7, 2025.

Who can apply for Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)?

Closed May 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

Who has been funded under PA-25-121?

NIH RePORTER lists 1 project funded under PA-25-121 in fiscal 2026, at 1 institution.

Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.

Similar open grants